Allergic Rhinitis
📧 Sign up to get email alerts when something new happens for Allergic Rhinitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis [NA]
The document describes an ongoing clinical trial evaluating the efficacy and safety of ganciclovir capsules for refractory moderate-to-sever…
-
CLINICAL_TRIALS trial_result · 2025-07-04Clinical Trial Update: Probiotic Ameliorates Adult Allergic Rhinitis and Modulates Gut Microbiota [NA]
A completed clinical trial assessed a probiotic product from Wecare Probiotics Co., Ltd. in adults with allergic rhinitis, reporting amelior…
-
FDA approval · 2025-07-01FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
The FDA approved a supplemental application for Montelukast Sodium from Ajanta Pharma USA Inc., under an ANDA.
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions [Phase 1]
Phase 1 study in healthy adults comparing the oral bioavailability of Bilastine 20 mg orally disintegrating tablet with Bilaxten (bilastine)…
-
EMA approval · 2025-06-27EMA Authorised: Avamys (fluticasone furoate) — GlaxoSmithKline Trading Services Limited
EMA has authorised Avamys (fluticasone furoate) nasal spray for allergic rhinitis, including seasonal and perennial forms.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-06-24FDA Approved: PROMETHAZINE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for promethazine hydrochloride from Hikma Pharmaceuticals USA, confirming the approval of a generic …
-
FDA approval · 2025-06-13FDA Approved: LEVOCETIRIZINE DIHYDROCHLORIDE — Supplemental Application (Marlex Pharmaceuticals Inc)
FDA approved a supplemental application for Levocetirizine Dihydrochloride from Marlex Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: Evaluation of Treatments for Allergic Rhinitis (Rhinal 2) [Phase 4]
Phase 4 clinical trial evaluating treatments for allergic rhinitis has completed. The snippet does not include study results.
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: Combination of Oral Supplement With Fatty Acids, Vitamin B6, Perilla, and Liquorice With Nasal Steroids for the Treatment of Allergic Rhinitis [EARLY_Phase 1]
A completed early-phase 1 clinical trial evaluating an oral supplement containing fatty acids, vitamin B6, Perilla, and licorice in combinat…
-
FDA approval · 2025-06-10FDA Approved: LEVOCETIRIZINE DIHYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for levocetirizine dihydrochloride from Chartwell RX, LLC.
-
CLINICAL_TRIALS trial_result · 2025-05-31Clinical Trial Update: Evaluation of Pediatric Massage in the Treatment of Allergic Rhinitis in Children [NA]
This clinical trial evaluated pediatric massage as a treatment for allergic rhinitis in children and the study has completed.
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study [EARLY_Phase 1]
An early Phase 1 trial from the University of Zurich evaluated immunological changes in lymph node tissue after intralymphatic immunotherapy…
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract [Phase 1, Phase 2]
This entry reports the completion of a Phase 1/2 clinical trial evaluating intralymphatic immunotherapy with Polvac grass and rye allergen e…
-
FDA approval · 2025-05-20FDA Approved: CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Sun Pharmaceutical Industries' Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride, updat…
-
FDA approval · 2025-05-14FDA Approved: CLARITIN CHEWABLE GRAPE AND BUBBLEGUM — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application to add a new chewable grape and bubblegum formulation of loratadine (Claritin) by Bayer HealthCare L…
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites [Phase 3]
Ongoing Phase 3 clinical trial evaluating the efficacy and safety of mite allergen immunotherapy for allergic rhinitis/rhinoconjunctivitis a…
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of a treatment for allergies to Cupressaceae and grasses, including allergic rhi…
-
FDA approval · 2025-05-09FDA Approved: NASACORT ALLERGY 24HR — Supplemental Application (Chattem, Inc.)
FDA approved a supplemental application for NASACORT ALLERGY 24HR (triamcinolone acetonide) from Chattem, Inc. This action represents a supp…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of a treatment for grass and olive pollen allergy is currently recruiting, targeti…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis [NA]
A clinical trial is evaluating the efficacy and safety of Arbidol (umifenovir) for treating allergic rhinitis, and the study is currently re…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects
An update on a clinical trial studying factors that affect tolerance to nasal birch pollen exposure in older adults with allergic rhinitis a…
-
CLINICAL_TRIALS trial_result · 2025-04-17Clinical Trial Update: Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children [Phase 3]
Phase 3 trial evaluating a fixed-dose combination of desloratadine and prednisolone for moderate-to-severe allergic rhinitis in children has…
-
FDA approval · 2025-04-17FDA Approved: FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE — Original Application (Aurohealth LLC)
FDA approved the original ANDA for a generic fixed-dose combination of fexofenadine hydrochloride and pseudoephedrine hydrochloride (Aurohea…
-
FDA approval · 2025-04-16FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Montelukast sodium (generic montelukast) submitted by Amneal Pharmaceuticals LLC under ANDA20510…
-
CLINICAL_TRIALS trial_result · 2025-04-10Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM) [Phase 3]
Phase 3 randomized, double-blind, placebo-controlled trial to assess the efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL subcutaneous immu…